Surgical treatment of small cell lung cancer.
From 1970 till 1989, 30 patients underwent surgical resection for small cell lung cancer (SCLC). The 5-year survival in stage I patients was 31%, in stage II 17% and in stage III the projected 5-year survival was 9%. Among N2 patients there were only 25% survivors after 1 year and none after 2 years. The first group of 15 patients (1970-1979) received no adjuvant chemotherapy in contrast to the second group of 15 patients (1980-1989). The overall 5-year survival for the first group was 13% and the estimated 5-year survival for the second group was 27%. In stage I SCLC, the 5-year survival was 12% and 60%, respectively. These results confirm that surgery may lead to long-term survival in stage I and possibly stage II SCLC, with better prognosis in stage I when adjuvant chemotherapy is added.
Coolen
L
L
Department of Pneumology, University Hospital Gasthuisberg, University of Leuven, Belgium.
Van den Eeckhout
A
A
Deneffe
G
G
Demedts
M
M
Vansteenkiste
J
J
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D016190:Carboplatin